SCHEMBL12084232

SCHEMBL12084232

Cc1nc(-c2cccc(F)c2)ncc1C(=O)Nn1ccc2cc(F)cnc21

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HPGDS O60760 7/20 0.54
▸ CSNK1D P48730 1/20 0.40
▸ DGAT1 O75907 1/20 0.38
▸ IDO1 P14902 2/20 0.37
▸ POLQ O75417 1/20 0.36
▸ MAP4K4 O95819 1/20 0.36
▸ WNT3A P56704 1/20 0.35
▸ MEN1 O00255 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ JAK2 O60674 1/20 0.34
▸ JAK1 P23458 1/20 0.34
▸ TYK2 P29597 1/20 0.34
▸ JAK3 P52333 1/20 0.34
▸ MAPK14 Q16539 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3221574 0.89 HPGDS (0.53) HPGDSCSNK1DDGAT1IDO1POLQ
SCHEMBL3217764 0.87 HPGDS (0.54) HPGDSCSNK1DDGAT1IDO1POLQ
SCHEMBL2471757 0.85 HPGDS (0.54) HPGDSCSNK1DDGAT1POLQMAP4K4
SCHEMBL14313262 0.84 HPGDS (0.42) HPGDSCSNK1DIDO1POLQWNT3A
SCHEMBL12083859 0.83 HPGDS (0.63) HPGDSMEN1KMT2A
SCHEMBL3220594 0.83 HPGDS (0.52) HPGDSCSNK1DDGAT1MAPTJAK2
SCHEMBL12083909 0.82 HPGDS (0.51) HPGDSCSNK1DDGAT1POLQMAP4K4
SCHEMBL3810374 0.82 HPGDS (0.51) HPGDSCSNK1DDGAT1IDO1POLQ
SCHEMBL3223201 0.82 HPGDS (0.59) HPGDSCSNK1DDGAT1POLQMAP4K4
SCHEMBL14041378 0.81 HPGDS (0.51) HPGDSCSNK1DDGAT1IDO1POLQ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2142516-B1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI SA (FR) 2012-12-26 — — EP disclosed
US-8258130-B2 Pyrimidine hydrazide compounds as PGDS inhibitors SANOFI (FR) 2012-09-04 — — US disclosed
US-8258130-B2 Pyrimidine hydrazide compounds as PGDS inhibitors SANOFI (FR) 2012-09-04 — — US disclosed
US-20100048568-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2010-02-25 — — US disclosed
US-20100048568-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2010-02-25 — — US disclosed
WO-2008121670-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2008-10-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048568-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS HRH2, HRH1, HRH4 HPGDS 10/4885CSNK1D 1144/4885DGAT1 3570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback